Business
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with at Least One Tumor Assessment as of Data Cutoff Seven Complete Responses (CR) and Five Partial Responses (PR) were Observed for an Overall Response Rate (ORR) of 63% and CR Rate of 37%Higher Response Rates Observed in CAR T Naïve Patients (N=16) with an ORR of 75% and CR Rate of 44%Nine of 12 (75%) Patients Remain in Response as of the Data CutoffHigher Dose ALLO-647 Associated with Higher CR Rates Phase 1 Trial Initiated for ALLO-501A, a Next Generation Anti-CD19 AlloCAR T™ Candidate Intended for Phase 2 DevelopmentCompany to Host a Live Webinar on Friday, May 29 at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif. and PARIS, France, May 29, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with development partner Servier, an independent international pharmaceutical company, today announced positive initial results from Allogene’s dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL). Data were presented at the American Society of Clinical Oncology (ASCO) annual meeting. This study utilizes ALLO-647, Allogene's anti-CD52 monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen.\n “We are very pleased with these initial Phase 1 results, which indicated that ALLO-501 and ALLO-647 were well tolerated and produced complete responses in patients with advanced NHL,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Based on these results, we believe we are on the right trajectory to make AlloCAR T therapy a reality for patients.” “Allogeneic CAR T therapies provide an off-the-shelf option that may make cellular therapies available to more patients,” said Sattva S. Neelapu, M.D., Professor, Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas. “While longer follow-up is required, the response to ALLO-501 appears promising with 75% of pat...